World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
83
Citations
20973
World Ranking
1013
National Ranking
464

Overview

Ana Espinel-Ingroff is affiliated with Virginia Commonwealth University Medical Center in the United States. Their research primarily focuses on the field of medicine, with significant contributions to epidemiology, infectious diseases, cell biology, plant science, and molecular biology. The scientist's work centers around topics such as antifungal resistance and susceptibility, fungal infections and studies, nail diseases and treatments, plant pathogens and fungal diseases, mycotoxins in agriculture and food, as well as fungal and yeast genetics research.

They have published extensively in various scientific venues, with the most frequent publications appearing in:

  • Journal of Fungi (6 publications)
  • Pathogens (1 publication)
  • Antimicrobial Agents and Chemotherapy (1 publication)
  • Current Fungal Infection Reports (1 publication)

Recent notable papers authored or coauthored by Ana Espinel-Ingroff include:

  • "Antifungal Resistance among Less Prevalent Candida Non-albicans and Other Yeasts versus Established and under Development Agents: A Literature Review," 2021, Journal of Fungi
  • "Antifungal Resistance in Cryptococcal Infections," 2024, Pathogens
  • "Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent Candida spp. to Triazoles and Amphotericin B and Aspergillus spp. to Caspofungin: Further Assessment of Modal Variability," 2021, Antimicrobial Agents and Chemotherapy
  • "Commercial Methods for Antifungal Susceptibility Testing of Yeasts: Strengths and Limitations as Predictors of Resistance," 2022, Journal of Fungi
  • "A Mini-Review of In Vitro Data for Candida Species, Including C. auris, Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin," 2024, Journal of Fungi

The frequent co-authors working with Ana Espinel-Ingroff include Rafael Cantón, Éric Dannaoui, Márcia de Souza Carvalho Melhem, Diniz Pereira Leite Júnior, and Juliana Possatto Fernandes Takahashi. The collaboration with these co-authors spans various aspects of antifungal research and susceptibility testing.

Their research extensively addresses antifungal resistance and susceptibility, encompassing both common and less prevalent Candida species and other yeasts. This includes evaluating methods for antifungal susceptibility testing, resistance detection in fungal pathogens, and reviews of antifungal agents currently established or under development.

The scientific work by Ana Espinel-Ingroff contributes to understanding fungal infections and resistance mechanisms, including studies on nail diseases and the impact of fungal pathogens on plant health and mycotoxin presence in agriculture and food. The diversity of research topics reflects a multidisciplinary approach within the overarching medical and biological sciences fields.

Best Publications

  • Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections

    John H. Rex;Michael A. Pfaller;John N. Galgiani;Marilyn S. Bartlett

  • Voriconazole Treatment for Less-Common, Emerging, or Refractory Fungal Infections

    John R. Perfect;Kieren A. Marr;Thomas J. Walsh;Richard N. Greenberg

  • Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts

    Ana Espinel-Ingroff

  • Antifungal Susceptibility Testing: Practical Aspects and Current Challenges

    John H. Rex;Michael A. Pfaller;Thomas J. Walsh;Vishnu Chaturvedi

  • In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens

    Ana Espinel-Ingroff

  • Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods

    M.A. Pfaller;D. Andes;D.J. Diekema;A. Espinel-Ingroff

  • In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi

    Ana Espinel-Ingroff

  • Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.

    A Espinel-Ingroff;K Dawson;M Pfaller;E Anaissie

  • In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.

    Ana Espinel-Ingroff;Kathleen Boyle;Daniel J. Sheehan

  • Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

    A Espinel-Ingroff;C W Kish;T M Kerkering;R A Fromtling

  • Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints

    M. A. Pfaller;D. J. Diekema;J. H. Rex;A. Espinel-Ingroff

  • In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.

    Ana Espinel-Ingroff

  • Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents

    A. L. Barry;M. A. Pfaller;S. D. Brown;A. Espinel-Ingroff

  • Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.

    R A Fromtling;J N Galgiani;M A Pfaller;A Espinel-Ingroff

  • Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.

    A. Espinel-Ingroff;M. Bartlett;R. Bowden;N. X. Chin

  • Testing Conditions for Determination of Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Aspergillus spp.: NCCLS Collaborative Study

    A. Espinel-Ingroff;A. Fothergill;J. Peter;M. G. Rinaldi

  • Collaborative investigation of variables in susceptibility testing of yeasts.

    M A Pfaller;M G Rinaldi;J N Galgiani;M S Bartlett

  • Comparison of the E-test with the NCCLS M38-P Method for Antifungal Susceptibility Testing of Common and Emerging Pathogenic Filamentous Fungi

    Unknown

  • Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)

    A. Espinel-Ingroff;D. J. Diekema;A. Fothergill;Elizabeth Johnson

  • Optimizing the Correlation between Results of Testing In Vitro and Therapeutic Outcome In Vivo for Fluconazole by Testing Critical Isolates in a Murine Model of Invasive Candidiasis

    John H. Rex;Page W. Nelson;Victor L. Paetznick;Mario Lozano-Chiu

  • Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole

    A. Espinel-Ingroff;A.I. Aller;E. Canton;L.R. Castanon-Olivares

  • Antifungal Susceptibility Testing of Filamentous Fungi

    Ana Espinel-Ingroff;Emilia Cantón;Javier Pemán

Frequent Co-Authors

Javier Pemán
Javier Pemán Hospital Universitari i Politècnic La Fe
Michael A. Pfaller
Michael A. Pfaller JMI Laboratories
John D. Turnidge
John D. Turnidge University of Adelaide
Mahmoud A. Ghannoum
Mahmoud A. Ghannoum Case Western Reserve University
Michael G. Rinaldi
Michael G. Rinaldi The University of Texas Health Science Center at San Antonio
Teresa Peláez
Teresa Peláez Hospital General Universitario Gregorio Marañón
Jacques F. Meis
Jacques F. Meis Canisius-Wilhelmina Ziekenhuis
Manuel Cuenca-Estrella
Manuel Cuenca-Estrella Instituto de Salud Carlos III
Thomas J. Walsh
Thomas J. Walsh Weill Cornell Medicine
Josep Guarro
Josep Guarro Rovira i Virgili University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens various career avenues, but it's also valuable to consider related online degrees that can complement or diversify your skill set. For instance, healthcare fields like becoming a child life specialist salary with bachelor degree offer meaningful work with a strong salary outlook, often accessible with a relevant undergraduate degree.

For individuals facing unique challenges, such as a criminal record, it’s encouraging to know there are online colleges that accept felons. These programs provide opportunities for second chances and can lead to rewarding careers within or outside microbiology.

Exploring healthcare options further, pursuing a path toward becoming a functional medicine nurse salary can be lucrative and impactful. Such specialized nursing roles often integrate biological sciences, making microbiology knowledge beneficial.

Finally, careers in health information management, like obtaining a certified professional coder certification, offer stable employment with growth potential. This certification aligns with microbiology graduates interested in medical billing, coding, and healthcare administration.

Best Scientists Citing Ana Espinel-Ingroff

Trending Scientists

Recently Published Articles